Trimetazidine is a drug that has been banned in the United States since 2011.
The US Food and Drug Administration (FDA) has banned the use of trimetazidine, a drug used to treat angina, in the United States. Trimetazidine was previously approved by the FDA in 1996 and was sold under the brand name Tzamal. However, it was discontinued from market in 2011 after being linked to a number of side effects including kidney failure and bone marrow suppression. The drug is still available for use outside of the US but is not approved for use by any regulatory body within Europe.
What is trimetazidine?
Trimetazidine is a drug that acts as an alpha-adrenergic receptor antagonist, which means it blocks adrenergic receptors from responding to adrenaline. Adrenaline plays an important role in regulating blood pressure and heart rate, so blocking these receptors can cause issues with both of these functions.
How does trimetazidine work?
“What is trimetazidine used for?”
Trimetazidine works by blocking adrenaline receptors (alpha-adrenergic) from responding to adrenaline. Adrenaline plays an important role in regulating blood pressure and heart rate so blocking these receptors can cause issues with both of these functions.
“How does trimetazidine work?”
The main function of trimetazidine is to lower blood pressure.
“How does trimetazidine work?”
Trimetazidines ability to lower blood pressure derives from its ability to block alpha-adrenergic receptors. Blocking these receptors causes vasodilation, or widening of blood vessels.
“What are alpha-adrenergic receptors?”
Alpha-adrenergic receptors are stimulated by adrenaline and noradrenaline; they are also known as sympathetic adrenoceptors.
“What are beta-adrenergic receptors?”
Beta-adrenergic receptors are stimulated by epinephrine; they are also known as parasympathetic adrenoceptors.
